A Randomized Trial of Maintenance Therapy for Vasculitis Associated with Antineutrophil Cytoplasmic Autoantibodies
The DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.
Abstract
Background The primary systemic vasculitides usually associated with autoantibodies to neutrophil cytoplasmic antigens include Wegener's granulomatosis and microscopic polyangiitis. We investigated whether exposure to cyclophosphamide in patients with generalized vasculitis could be reduced by substitution of azathioprine at remission. Methods We studied patients with a new diagnosis of generalized vasculitis and a serum creatinine concentration of 5.7 mg per deciliter (500 micromol per liter) or less. All patients received at least three months of therapy with oral cyclophosphamide and prednisolone. After remission, patients were randomly assigned to continued cyclophosphamide therapy (1.5 mg per kilogram of body weight per day) or a substitute regimen of azathioprine (2 mg per kilogram per day). Both groups continued to receive prednisolone and were followed for 18 months from study entry. Relapse was the primary end point. Results Of 155 patients studied, 144 (93 percent) entered remission and were randomly assigned to azathioprine (71 patients) or continued cyclophosphamide (73 patients). There were eight deaths (5 percent), seven of them during the first three months. Eleven relapses occurred in the azathioprine group (15.5 percent), and 10 occurred in the cyclophosphamide group (13.7 percent, P=0.65). Severe adverse events occurred in 15 patients during the induction phase (10 percent), in 8 patients in the azathioprine group during the remission phase (11 percent), and…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Treatment includes prednisone, cyclophosphamide, or methotrexate.237,238,245”
From International Consensus Statement on Allergy and Rhinology: Allergic Rhinitis (2018) · cites this paper as [245]
Citations
Cites
(1992) · PubMed · Cited by 33,716
The MOS 36-ltem Short-Form Health Survey (SF-36): I. Conceptual Framework and Item Selection
Ware, J. E., & Sherbourne, C. D. (1992) · Medical Care · doi:10.1097/00005650-199206000-00002 · Cited by 30,033
Nomenclature of Systemic Vasculitides
Jennette, J. C., Falk, R. J., Andrassy, K., Bacon, P. A., Churg, J., Gross, W. L., Hagen, E. C., Hoffman, G. S., Hunder, G. G., Kallenberg, C. G. M., et al. (1994) · Arthritis & Rheumatism · doi:10.1002/art.1780370206 · Cited by 3,845
Self-citationWegener Granulomatosis: An Analysis of 158 Patients
Hoffman, G. S., Kerr, G. S., Leavitt, R. Y., Hallahan, C. W., Lebovics, R. S., Travis, W. D., Rottem, M., & Fauci, A. S. (1992) · Annals of Internal Medicine · doi:10.7326/0003-4819-116-6-488 · Cited by 2,857
FAUCI, A. S., HAYNES, B. F., KATZ, P., & WOLFF, S. M. (1983) · Annals of Internal Medicine · doi:10.7326/0003-4819-98-1-76 · Cited by 2,001
Short form 36 (SF36) health survey questionnaire: normative data for adults of working age.
Jenkinson, C., Coulter, A., & Wright, L. (1993) · BMJ · doi:10.1136/bmj.306.6890.1437 · Cited by 1,718
Falk, R. J., Terrell, R. S., Charles, L. A., & Jennette, J. C. (1990) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.87.11.4115 · Cited by 1,261
Birmingham Vasculitis Activity Score (BVAS) in systemic necrotizing vasculitis.
Luqmani, R. A., BACON, P. A., Moots, R. J., Janssen, B. A., Pall, A. A., Emery, P., Savage, C. O. S., & Adu, D. (1994) · PubMed · Cited by 1,056
Self-citationSavige, J., Gillis, D., Benson, E., Davies, D., Esnault, V., Falk, R. J., Chris Hagen, E., Jayne, D., Charles Jennette, J., Paspaliaris, B., et al. (1999) · American Journal of Clinical Pathology · doi:10.1093/ajcp/111.4.507 · Cited by 884
Self-citationValidation of rheumatoid arthritis improvement criteria that include simplified joint counts
van Gestel, A. M., Haagsma, C. J., & van Riel, P. L. C. M. (1998) · Arthritis & Rheumatism · doi:10.1002/1529-0131(199810)41:10<1845::aid-art17>3.0.co;2-k · Cited by 803
Research works printed but not linked: 10
- Jennette JC, 1989, Am J Pathol, 135, 921
- Hauer HA, 1998, Clin Exp Immunol, 112, 28
- 10.1002/(SICI)1096-9896(200002)190:3<349::AID-PATH524>3.0.CO;2-A · doi:10.1002/(sici)1096-9896(200002)190:3<349::aid-path524>3.0.co;2-a
- 10.1002/1529-0131(200005)43:5<1021::AID-ANR10>3.0.CO;2-J · DOI · Paper page
- Jayne DR, 1995, QJM, 88, 127
- Luqmani RA, 1994, QJM, 87, 671
- Bacon PA, 1995, Clin Exp Rheumatol, 13, 275
- 10.1002/1529-0131(199810)41:10<1835::AID-ART16>3.0.CO;2-Q · doi:10.1002/1529-0131(199810)41:10<1835::aid-art16>3.0.co;2-q
- Szpirt WM, 1996, Int J Artif Organs, 19, 501
- 10.1002/1529-0131(200105)44:5<1149::AID-ANR197>3.0.CO;2-F · DOI · Paper page
Cited by
Items 601–700 of 999
Jayne, D. R. W., Walsh, M. W., Merkel, P. A., Peh, C. A., Szpirt, W. M., Puéchal, X., Fujimoto, S., Hawley, C. M., KHALIDI, N. A., Jones, R. B., et al. (2022) · Health Technology Assessment · doi:10.3310/pnxb5040 · Cited by 15
“Cardiovascular 104 69 (20) 72 55 (16) 176 124 (18) Endocrine 10 9 (3) 3 3 (1) 13 12 (2) Gastrointestinal 45 34 (10) 55 39 (11) 100 73 (10) Haematological 28 25 (7) 18 16 (5) 46 41 (6) Infection 227 136 (39) 196 114 (32) 423 250 (36) Renal 50 41 (12) 53 36 (10) 103 77 (11) Surgery 19 16 (5) 15 13 (4) 34 29 (4) Vasculit…”
Self-citationDiagnostik und Therapie der ANCA-assoziierten Vaskulitiden
Holle, J. U., Kubacki, T., Aries, P., Hellmich, B., Kernder, A. L., Kneitz, C., Lamprecht, P., Schirmer, J. H., Schreiber, A., Berlit, P., et al. (2025) · Zeitschrift für Rheumatologie · doi:10.1007/s00393-024-01597-6 · Cited by 17
Latimer, N. R., Carroll, C., Wong, R., Tappenden, P., Venning, M. C., & Luqmani, R. A. (2014) · PharmacoEconomics · doi:10.1007/s40273-014-0189-z · Cited by 13
“Therapies used to treat AAV are themselves also associated with substantial toxicities, which frequently result in severe and permanent patient morbidity and mortality [38].”
BackgroundPauci-immune glomerulonephritis in children: A clinicopathologic study of 21 patients
Khalighi, M. A., Wang, S., Henriksen, K., Bock, M., Keswani, M., Chang, A., & Meehan, S. M. (2015) · Pediatric Nephrology · doi:10.1007/s00467-014-2970-9 · Cited by 13
Hessels, A. C., Rutgers, A., Sanders, J., & Stegeman, C. A. (2018) · PLoS ONE · doi:10.1371/journal.pone.0195524 · Cited by 13
“The frequency of leukopenia in or population was relatively high compared to previous reports, such as in the CYCAZAREM trial (30%).[5] The first reason for this is that patients with leukopenia at the start of azathioprine therapy were also scored as having leukopenia during azathioprine therapy.”
InfluentialBonatti, F., Adorni, A., Percesepe, A., Vaglio, A., & Martorana, D. (2019) · Rare diseases of the immune system · doi:10.1007/978-3-030-03934-9_6 · Cited by 13
New lung mass in a patient with granulomatosis with polyangiitis
Masiak, A., Fijałkowska, J., Nowakowski, S., Smoleńska, Ż., & Zdrojewski, Z. (2020) · Rheumatology International · doi:10.1007/s00296-020-04646-w · Cited by 14
“Doberstein (2017) [20] 1 69, M Eye, lung 2 NR Yes Died”
BackgroundMethodHosokawa, Y., Okada, M., Suemori, K., Hamaguchi, N., Miyoshi, K., Takagi, T., Teraoka, M., Yamada, H., Ishizaki, J., Matsumoto, T., et al. (2021) · Auris Nasus Larynx · doi:10.1016/j.anl.2021.01.023 · Cited by 13
Sanders, J., Abdulahad, W. H., Stegeman, C. A., & Kallenberg, C. G. M. (2014) · Nephron Clinical Practice · doi:10.1159/000368570 · Cited by 13
Kaya, H., Yılmaz, S., Sezgı, C., Abakay, Ö., Taylan, M., Şen, H. S., Demir, M., Akkurt, Z. M., & Şenyiğit, A. (2014) · Respiratory Medicine Case Reports · doi:10.1016/j.rmcr.2014.09.002 · Cited by 13
“When administered shortly after the induction therapy, combined immunosuppressive therapy ensures remission in up to 90% of patients within 6 months [12].”
Pulmonary Vasculitis in the Intensive Care Unit
Diaz, J., CALAMIA, K. T., & Lee, A. S. (2011) · Journal of Intensive Care Medicine · doi:10.1177/0885066610384551 · Cited by 13
“Maintenance therapy or regimens after the initial remission induction will not be discussed, though there have been considerable advances in this area as well for specific vasculitic conditions.(60,65) If a life-threatening or organ-threatening immune-mediated inflammatory process is diagnosed or is highly suspected a…”
BackgroundBellos, I., Michelakis, I., & Nikolopoulos, D. (2020) · Clinical Rheumatology · doi:10.1007/s10067-020-05390-z · Cited by 13
Granulomatose avec polyangéite (maladie de Wegener)
Karras, A., Guiard, E., Levi, C., & Thervet, É. (2012) · La Presse Médicale · doi:10.1016/j.lpm.2012.06.007 · Cited by 13
A retrospective study on outcome of microscopic polyangiitis in chronic renal replacement therapy
Merino, J. L., Galeano, C., Espejo, B., Rivera, M. E., Fernández‐Lucas, M., Caldés, S., Plana, N., Letosa, M. M., Teruel, J. L., Quereda, C., et al. (2010) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfq523 · Cited by 13
Wang, C.-C., Shiang, J.-C., Tsai, M.-K., Chen, I.-H., Lin, S., Chu, P., & Wu, C. (2009) · Clinical Rheumatology · doi:10.1007/s10067-009-1264-2 · Cited by 13
van Laar, J. M. (2013) · Elsevier eBooks · doi:10.1016/b978-1-4377-1738-9.00062-1 · Cited by 15
Eosinophilic myocarditis: from etiology to diagnostics and therapy
Russo, M., Ismibayli, Z., Antonaci, S., & Piccinni, G. C. (2023) · Minerva Cardiology and Angiology · doi:10.23736/s2724-5683.23.06297-x · Cited by 18
Cardiovascular Disease in Anti-neutrophil Cytoplasm Antibody-Associated Vasculitis
Sayer, M., Chapman, G. B., Thomas, M., & Dhaun, N. (2023) · Current Rheumatology Reports · doi:10.1007/s11926-023-01123-8 · Cited by 15
“The CYCA-ZAREM (Cyclophosphamide versus Azathioprine for Early Remission Phase of Vasculitis) trial compared oral cyclophosphamide with azathioprine as maintenance therapy in AAV [58].”
ResultSharma, P., Zonozi, R., & Geetha, D. (2024) · Advances in Kidney Disease and Health · doi:10.1053/j.akdh.2024.04.005 · Cited by 16
Frary, E. C., Hess, S., Gerke, O., & Laustrup, H. (2017) · Medicine · doi:10.1097/md.0000000000007613 · Cited by 12
Eosinophilic granulomatosis with polyangiitis
Nanzer, A. M., & Wechsler, M. E. (2022) · European Respiratory Society eBooks · doi:10.1183/2312508x.10029820 · Cited by 13
Hing, A., Wong, W., Looi, L., Ratnasingam, J., & Lim, S. K. (2022) · Case Reports in Nephrology and Dialysis · doi:10.1159/000525182 · Cited by 12
Vasculitis assessment and Takayasu aorto-arteritis
Bacon, P., Rajappa, S. M., Danda, D., & Misra, R. (2012) · Indian Journal of Rheumatology · doi:10.1016/j.injr.2012.07.001 · Cited by 12
Self-citationSaiga, K., Tokunaka, K., Ichimura, E., Toyoda, E., Abe, F., Yoshida, M., Furukawa, H., Nose, M., & Ono, M. (2006) · Arthritis & Rheumatism · doi:10.1002/art.22187 · Cited by 12
Pai, S., & Panda, M. (2008) · Cases Journal · doi:10.1186/1757-1626-1-417 · Cited by 12
Shimoi, T., Shojima, K., Murota, A., Takizawa, Y., Maruyama, J., & Setoguchi, K. (2012) · PubMed · Cited by 14
Management of Small Vessel Vasculitides
Lopalco, G., Rigante, D., Venerito, V., Emmi, G., Anelli, M. G., Lapadula, G., Iannone, F., & Cantarini, L. (2016) · Current Rheumatology Reports · doi:10.1007/s11926-016-0580-1 · Cited by 13
Puéchal, X., Iudici, M., Pagnoux, C., Karras, A., Cohen, P., Maurier, F., Quéméneur, T., Lifermann, F., Hamidou, M. A., Mouthon, L., et al. (2020) · Arthritis & Rheumatology · doi:10.1002/art.41551 · Cited by 12
“therapeutic approach, with the use of glucocorticoids (GCs) combined with cyclophosphamide (CYC) or rituximab (RTX) to induce remission, followed by a remission-maintenance therapy to prevent relapses of disease (2).”
BackgroundInfluentialAnti-cytokine targeted therapies for ANCA-associated vasculitis
Bała, M. M., Malecka-Massalska, T. J., Koperny, M., Zając, J., Jarczewski, J. D., & Szczeklik, W. (2020) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd008333.pub2 · Cited by 15
Hémorragies intra-alvéolaires de l’adulte d’origine immunitaire
Picard, C., Parrot, A., Mayaud, C. M., & Cadranel, J. L. (2006) · Revue des Maladies Respiratoires · doi:10.1016/s0761-8425(06)73417-9 · Cited by 12
Advances in the Treatments of Systemic Vasculitides
Guillevin, L. (2008) · Clinical Reviews in Allergy & Immunology · doi:10.1007/s12016-007-8068-4 · Cited by 12
Targeting B Lymphocytes as Therapy for ANCA-Associated Vasculitis
Golbin, J. M., & Specks, U. (2007) · Rheumatic Disease Clinics of North America · doi:10.1016/j.rdc.2007.09.001 · Cited by 12
Vascularites associées aux anticorps anticytoplasme des polynucléaires
Puéchal, X. (2007) · Revue du Rhumatisme · doi:10.1016/j.rhum.2007.02.027 · Cited by 13
Difficult to diagnose manifestations of vasculitis: Does an interdisciplinary approach help?
Hellmich, B., & Gross, W. L. (2005) · Best Practice & Research Clinical Rheumatology · doi:10.1016/j.berh.2004.10.004 · Cited by 11
Self-citationRituximab for Severe Refractory Pediatric Wegener Granulomatosis
Patel, A. M., & Lehman, T. J. A. (2008) · JCR Journal of Clinical Rheumatology · doi:10.1097/rhu.0b013e3181886064 · Cited by 12
“Currently methotrexate and/or azathioprine are used as maintenance therapy.(5,6) Both were used for this patient without sustained efficacy.”
MethodOutcome in small-vessel systemic vasculitis.
Luqmani, R. A., & Floßmann, O. (2006) · PubMed · Cited by 12
Rituximab in ANCA-Associated Vasculitis: Fad or Fact?
Fervenza, F. C. (2010) · Nephron Clinical Practice · doi:10.1159/000321437 · Cited by 12
Clain, J. M., Cartin‐Ceba, R., Fervenza, F. C., & Specks, U. (2013) · Therapeutic Advances in Musculoskeletal Disease · doi:10.1177/1759720x13516239 · Cited by 11
“The cumulative exposure of patients to CYC has been further curtailed by the practice of converting patients to long-term maintenance therapy with MTX or azathioprine (AZA) following 3–6 months of treatment with CYC and GCS for remission induction [Sneller et al. 1995; Jayne et al. 2003].”
BackgroundMarinopoulos, S. S., Coylewright, M. J., Auwaerter, P. G., & Flynn, J. A. (2010) · New England Journal of Medicine · doi:10.1056/nejmcps0808968 · Cited by 11
Zhang, Y., Wu, Y., Ciorba, M. A., & Ouyang, Q. (2008) · World Journal of Gastroenterology · doi:10.3748/wjg.14.622 · Cited by 11
Prolonged Duration of Renal Recovery Following ANCA-Associated Glomerulonephritis
Oomatia, A., Moran, S. M., Kennedy, C., Sequeira, R., Hamour, S., Burns, A. P., Little, M. A., & Salama, A. D. (2016) · American Journal of Nephrology · doi:10.1159/000444925 · Cited by 11
Gopaluni, S., & Jayne, D. R. W. (2016) · Current Treatment Options in Rheumatology · doi:10.1007/s40674-016-0045-8 · Cited by 11
Self-citationHazebroek, M. R., van Paassen, P., Dennert, R. M., & Heymans, S. R. B. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-803267-1.00020-x · Cited by 11
Pearce, F., McGrath, C. M., Sandhu, R. K., Packham, J., Watts, R. A., Rhodes, B., Al-Jayyousi, R., Harper, L., Obrenovic, K., & Lanyon, P. (2018) · Rheumatology Advances in Practice · doi:10.1093/rap/rky025 · Cited by 11
Investigations in systemic vasculitis – The role of renal pathology
Berden, A. E., Trejo, M. A. C. W., & Bajema, I. M. (2018) · Best Practice & Research Clinical Rheumatology · doi:10.1016/j.berh.2018.10.010 · Cited by 11
Koukoulaki, M., & Iatrou, C. (2019) · World Journal of Nephrology · doi:10.5527/wjn.v8.i4.75 · Cited by 11
Clerté, M., Philip, R., Levi, C., Gall, É. C.-L., Audard, V., Huart, A., Puéchal, X., Touzot, M., Rabot, N., Thervet, É., et al. (2021) · Scandinavian Journal of Rheumatology · doi:10.1080/03009742.2021.1920120 · Cited by 11
“003 s (sclerotic) 6 (19) 12 (27) c (crescentic) 22 (71) 16 (37) f (focal) 0 11 (25) m (mixed) 3 (10) 5 (11) Brix renal risk score (n = 27) (n = 44) 0.”
BackgroundSorin, B., Samson, M., Durel, C., Diot, É., Guichard, I., Grados, A., Limal, N., Régent, A., Cohen, P., Dion, J., et al. (2021) · Lara D. Veeken · doi:10.1093/rheumatology/keab791 · Cited by 11
Wendt, M., Börjesson, O., Avik, A., Bratt, J., Anderstam, B., Qureshi, A. R., Miller, E. J., Gunnarsson, I., & Bruchfeld, A. N. (2013) · Molecular Medicine · doi:10.2119/molmed.2012.00352 · Cited by 11
“Typically, AAV is treated initially with high doses of glucocorticoids (GC) in combination with cyclophosphamide (CYC) (3) methotrexate (MTX) (4) or rituximab (5,6) followed by a maintenance treatment with azathioprine (AZA) and low dose GC (7).”
BackgroundModern management of primary systemic vasculitis
Lapraik, C., Watts, R. A., & Scott, D. G. I. (2007) · Clinical Medicine · doi:10.7861/clinmedicine.7-1-43 · Cited by 11
Abe, Y., Tamura, N., Yang, K., Matsuoka, J., Kon, T., Yamaji, K., Hashimoto, H., Tsuda, H., & Takasaki, Y. (2016) · Modern Rheumatology · doi:10.1080/14397595.2016.1205778 · Cited by 11
Alveolar Hemorrhage and Rare Infiltrative Diseases
Collard, H. R., King, T. E., & Schwarz, M. I. (2015) · Elsevier eBooks · doi:10.1016/b978-1-4557-3383-5.00067-1 · Cited by 11
Bagga, A. (2009) · Springer eBooks · doi:10.1007/978-3-540-76341-3_34 · Cited by 11
ANCA-associated vasculitis: new options beyond steroids and cytotoxic drugs
Selamet, U., Kovaliv, Y. B., Savage, C. O. S., & Harper, L. (2007) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.16.5.689 · Cited by 11
“This supports an early change to less toxic azathioprine when the patient has entered remission [56].”
BackgroundIntravenous immunoglobulin as adjuvant therapy for Wegener's granulomatosis
Fortin, P. M., Tejani, A. M., Bassett, K. L., & Musini, V. M. (2009) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007057.pub2 · Cited by 11
Rapid-progressive Glomerulonephritis
Haubitz, M. (2019) · Der Internist · doi:10.1007/s00108-019-0575-x · Cited by 10
Moiseev, S. V., Bulanov, N. M., Crnogorac, M., Di̇reskeneli̇, H., Gales̃ić, K., Gazel, Ü., Geetha, D., Guillevin, L., Hrušková, Z., Little, M. A., et al. (2023) · The Journal of Rheumatology · doi:10.3899/jrheum.220851 · Cited by 10
Self-citationTonutti, A., Pugliese, N., Ceribelli, A., Isailovic, N., Santis, M. D., Colapietro, F., Nicola, S. D., Polverini, D., Selmi, C. F., & Aghemo, A. (2024) · Seminars in Arthritis and Rheumatism · doi:10.1016/j.semarthrit.2024.152467 · Cited by 12
Oxford Desk Reference: Rheumatology
Hall, F. C., & Marshall, T. (2009) · Oxford University Press eBooks · doi:10.1093/med/9780199229994.001.0001 · Cited by 11
ANCA-Associated Vasculitis Clinical Presentation and Clinical Predictors of Relapse in Saudi Arabia
Alahmari, H. S., Daajani, H. A., Alsayed, F., & Alrashid, A. (2021) · Open Access Rheumatology Research and Reviews · doi:10.2147/oarrr.s314421 · Cited by 10
Discontinuation of therapies in vasculitis.
Luqmani, R. A. (2013) · PubMed · Cited by 10
Clinical trials on systemic necrotizing vasculitides
Guillevin, L. (2010) · La Presse Médicale · doi:10.1016/j.lpm.2009.12.004 · Cited by 10
“However, cyclophosphamide pulses, especially when their intervening intervals were lengthened after remission was obtained [22], did not maintain remission, once again emphasizing that a continuous-but-less-toxic therapy should be prescribed once remission is achieved [20].”
BackgroundMethodResultInfluentialTreatment of Severe and/or Refractory ANCA-Associated Vasculitis
Guillevin, L. (2014) · Current Rheumatology Reports · doi:10.1007/s11926-014-0430-y · Cited by 10
The Prevalence and Management of Pauci-Immune Glomerulonephritis and Vasculitis in Western Countries
Lionaki, S., & Boletis, J. (2015) · Kidney Diseases · doi:10.1159/000442062 · Cited by 10
Guillevin, L. (2020) · La Presse Médicale · doi:10.1016/j.lpm.2020.104034 · Cited by 10
Itabashi, M., Takei, T., Moriyama, T., Shiohira, S., Shimizu, A., Tsuruta, Y., Uchida, K., & Nitta, K. (2013) · Modern Rheumatology · doi:10.3109/14397595.2013.852836 · Cited by 10
“prognosis, with remission being achieved in over 90 % of patients [6].”
BackgroundTratamiento de las vasculitis sistémicas asociadas a ANCA
de Larrinoa, Í. R.-F. F., & Arruabarrena, C. E. (2009) · Reumatología Clínica · doi:10.1016/j.reuma.2009.01.009 · Cited by 13
Ocular manifestations of Wegener’s granulomatosis
Isa, H. M., Lightman, S., Pusey, C. D., & Taylor, S. R. J. (2011) · Expert Review of Ophthalmology · doi:10.1586/eop.11.62 · Cited by 10
Self-citationTreatment of renal manifestations of ANCA-associated Vasculitis
Gales̃ić, K., Ljubanović, D. G., & Horvatić, I. (2013) · Journal of Nephropathology · doi:10.5812/nephropathol.8971 · Cited by 10
“The role of azathioprine in the maintenance therapy in patients with ANCA vasculitis was examined as an alternative to a prolonged course of cyclophosphamide (32).”
BackgroundImmunosuppressive and Cytotoxic Therapy: Pharmacology, Toxicities, and Monitoring
Wang, T. S., Weigt, S. S., Belperio, J. A., & Lynch, J. P. (2011) · Seminars in Respiratory and Critical Care Medicine · doi:10.1055/s-0031-1279831 · Cited by 10
Lee, I. H., Kang, G. W., & Kim, K. C. (2016) · Rheumatology International · doi:10.1007/s00296-016-3489-0 · Cited by 10
“Considering the diagnostic criteria for minor relapse in ANCA-associated vasculitis (BVAS/WG ≥ 3), there is no sufficient clinical evidence supporting increased activity or relapse of GPA in this patient [31].”
Backgroundvan Laar, J. M. (2016) · Elsevier eBooks · doi:10.1016/b978-0-323-31696-5.00062-0 · Cited by 11
Conventional and biological immunosuppressants in vasculitis
Guillevin, L., Mukhtyar, C. B., Pagnoux, C., & Yates, M. M. (2018) · Best Practice & Research Clinical Rheumatology · doi:10.1016/j.berh.2018.07.006 · Cited by 10
Slot, M. C., & Tervaert, J. W. C. (2004) · Autoimmunity · doi:10.1080/08916930410001708724 · Cited by 10
“[3 – 6] Relapse is more common in patients with WG as compared to patients with another AAV subtype, MPA.”
BackgroundSelf-citationDhaygude, A. P., Griffith, M. E., Cairns, T. D. H., Mclean, A. G., Palmer, A., & Taube, D. H. (2004) · Nephron Clinical Practice · doi:10.1159/000079175 · Cited by 10
Translational research in autoimmunity: aims of therapy in vasculitis
Watts, R. A., Harper, L., Jayne, D. R. W., Levy, J. B., Pusey, C. D., Savage, C. O. S., Scott, D. G. I., & Williams, J. H. (2005) · Lara D. Veeken · doi:10.1093/rheumatology/keh609 · Cited by 10
Self-citationLydon, E. J., Barisoni, L. M. C., & Belmont, M. H. (2009) · PubMed · Cited by 10
Bektaş, M., İnce, B., Zarali, S., Gülseren, Ü. A., Ük, E., Ağargün, B. F., Güzey, D. Y., Yalçınkaya, Y., Artım-Esen, B., Gül, A., et al. (2025) · Rheumatology International · doi:10.1007/s00296-025-05883-7 · Cited by 9
“In a prospective randomized control trial, the baseline mean score of VDI was 1.3, increasing to 2.5 at the 18-month follow-up [25].”
InfluentialChildhood antineutrophil cytoplasmic antibodies associated vasculitides
Twilt, M., & Benseler, S. M. (2013) · Current Opinion in Rheumatology · doi:10.1097/bor.0000000000000013 · Cited by 9
Treatment of ANCA-Associated Vasculitis: New Therapies and a Look at Old Entities
Zand, L., Specks, U., Sethi, S. M., & Fervenza, F. C. (2014) · Advances in Chronic Kidney Disease · doi:10.1053/j.ackd.2014.01.009 · Cited by 9
“MTX and azathioprine are viable options, and the choice may depend on the side-effect profile and tolerability of the drug by the individual patient.(14,83-85) MMF has been found to be associated with a higher relapse rate than azathioprine.”
BackgroundInfluentialBellos, I., Boletis, I. N., & Lionaki, S. (2022) · Kidney International Reports · doi:10.1016/j.ekir.2022.02.020 · Cited by 9
New indications for biological therapies
Catanoso, M., Pipitone, N., Magnani, L., Boiardi, L., & Salvarani, C. (2011) · Internal and Emergency Medicine · doi:10.1007/s11739-011-0667-7 · Cited by 14
Classification, diagnosis and treatment of ANCA-associated vasculitis
Moiseev, S. V. (2015) · World Journal of Rheumatology · doi:10.5499/wjr.v5.i1.36 · Cited by 9
Cabral, D. A., & Benseler, S. M. (2011) · Elsevier eBooks · doi:10.1016/b978-1-4160-6581-4.10034-2 · Cited by 10
Faurschou, M., Obel, N., & Baslund, B. (2018) · Scandinavian Journal of Rheumatology · doi:10.1080/03009742.2018.1461924 · Cited by 9
Τzouvelekis, Α., Karampitsakos, Τ., Bouros, E., Tzilas, V., Liossis, S. C., & Bouros, D. E. (2019) · Clinics in Chest Medicine · doi:10.1016/j.ccm.2019.06.002 · Cited by 9
Tieu, J., Smith, R., Basu, N., Brogan, P. A., D’Cruz, D. P., Dhaun, N., Floßmann, O., Harper, L., Jones, R. B., Lanyon, P., et al. (2019) · Lara D. Veeken · doi:10.1093/rheumatology/kez632 · Cited by 9
Self-citationGeetha, D., & Shah, S. (2015) · ImmunoTargets and Therapy · doi:10.2147/itt.s55516 · Cited by 9
Değer, S. M., Mutluay, R., Ebinç, F. A., Arınsoy, T., & Sindel, Ş. (2009) · Rheumatology International · doi:10.1007/s00296-009-0911-x · Cited by 9
“Azathioprine is an agent that can be used for the maintenance therapy for WG [ 6 ], although Westman et al [3] reported the relation between skin carcinomas and azathioprine usage.”
BackgroundClinical characteristics and outcome of pauci-immune glomerulonephritis in African Americans
Geetha, D., Poulton, C. J., Hu, Y., Seo, P., Mcgregor, J., Falk, R. J., & Hogan, S. L. (2013) · Seminars in Arthritis and Rheumatism · doi:10.1016/j.semarthrit.2013.11.011 · Cited by 9
“These death rates were lower than reported in some clinical trials [14,18,20] and similar compared to other cohorts [16,22,23,25,34].”
BackgroundResultInfluentialIssues in trial design for ANCA-associated and large-vessel vasculitis
Tarzi, R. M., Mason, J. C., & Pusey, C. D. (2014) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2014.67 · Cited by 9
Self-citationEstudio clínico-biológico y radiológico de la granulomatosis de Wegener en un hospital universitario
Blanco, J. J. R., Cerezo, J. G., Muñoz, E. V., Suárez‐García, I., Rodriguez, M. L., Gregorio, L. Y., Sánchez, I. T., & Hernández, F. (2005) · Revista Clínica Española · doi:10.1157/13078247 · Cited by 9
ANCA-associated vasculitides—lessons from the adult literature
Vamvakopoulos, J. E., Savage, C. O. S., & Harper, L. (2010) · Pediatric Nephrology · doi:10.1007/s00467-010-1496-z · Cited by 10
“In 2003, Jayne and colleagues from the European Vasculitis Study Groups (EUVAS) showed that there was no difference in relapse rates when patients were changed to azathioprine following remission induced by 3–6 months CPA compared to those receiving 12 months CPA [60].”
BackgroundDiagnosis and management of pulmonary vasculitis
Yunt, Z. X., Frankel, S. K., & Brown, K. K. (2012) · Therapeutic Advances in Respiratory Disease · doi:10.1177/1753465812454693 · Cited by 10
“Timing of this transition was addressed by the EUVAS-sponsored Cyclophosphamide versus Azathioprine for Remission in Generalized Vasculitis (CYCAZAREM) trial [Jayne et al. 2003].”
MethodHanaoka, H., Ota, Y., Takeuchi, T., & Kuwana, M. (2016) · Clinical Rheumatology · doi:10.1007/s10067-015-3162-0 · Cited by 9
“However, it is difficult to be used for patients without renal insufficiency, as is based on data from two randomized controlled trials that investigated patients with severe renal insufficiency [6, 7].”
BackgroundThe role of rituximab in the treatment of ANCA-associated vasculitides (AAV)
Daikeler, T. D., Kistler, A. D., Martin, P., Vogt, B., & Huynh‐Do, U. (2015) · Swiss Medical Weekly · doi:10.4414/smw.2015.14103 · Cited by 9
Hinojosa‐Azaola, A., & Jiménez-González, A. (2017) · Clinical Rheumatology · doi:10.1007/s10067-017-3721-7 · Cited by 9
Treatment of Vasculitis of the Nervous System
Younger, D. S. (2019) · Neurologic Clinics · doi:10.1016/j.ncl.2019.01.014 · Cited by 9
“First, the sequential replacement of CYC by AZA once remission was achieved, as in the CYCAZAREM study.(30) Second, the”
MethodSong, G. G., & Lee, Y. H. (2020) · Zeitschrift für Rheumatologie · doi:10.1007/s00393-020-00803-5 · Cited by 9
“Rituximab is an approved alternative to cyclophosphamide for remission induction, and is increasingly used to treat patients with relapsing or refractory disease [2].”
BackgroundWegener's granulomatosis in Finland in 1981–2000: risk of dialysis-dependent renal disease
Takala, J., Kautiainen, H., Finne, P., & Leirisalo‐Repo, M. (2011) · Scandinavian Journal of Rheumatology · doi:10.3109/03009742.2010.533693 · Cited by 9
Metadata
- Authors
- Jayne, D., Rasmussen, N., Andrassy, K., Bacon, P., Tervaert, J. W. C., Dadoniené, J., Ekstrand, A., Gaskin, G., Gregorini, G., de Groot, K., Gross, W., Hagen, E. C., Mirapeix, E., Pettersson, E., Siegert, C., Sinico, A., Tesar, V., Westman, K., & Pusey, C.
- Affiliations
- Addenbrooke's Hospital (GB)
- Rigshospitalet (DK)
- University of Birmingham (GB)
- Maastricht University (NL)
- University of Helsinki (FI)
- Imperial College London (GB)
- Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia (IT)
- University of Lübeck (DE)
- Hospital Clínic de Barcelona (ES)
- Leiden University Medical Center (NL)
- Azienda Ospedaliera Ospedale San Carlo Borromeo (IT)
- Lund University (SE)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2003-07-03
- Volume
- 349
- Issue
- 1
- Pages
- 36-44
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W1981535363
- Cited by
- 1,348
- References
- 44
- Citations by year
- 2026: 6 · 2025: 22 · 2024: 24 · 2023: 37 · 2022: 48 · 2021: 36 · 2020: 51 · 2019: 46 · 2018: 51 · 2017: 46 · 2016: 51 · 2015: 80 · 2014: 77 · 2013: 80 · 2012: 83
- FWCI
- 48.55
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- BOA (University of Milano-Bicocca) (submittedVersion)
- University of Birmingham Research Portal (University of Birmingham) (submittedVersion)
- Topics
- Health Sciences › Medicine › Rheumatology › Vasculitis and related conditions
- Health Sciences › Medicine › Ophthalmology › Ocular Diseases and Behçet’s Syndrome
- Health Sciences › Medicine › Rheumatology › Systemic Lupus Erythematosus Research
- Keywords
- ANCA-associated vasculitis, maintenance therapy, cyclophosphamide, azathioprine, granulomatosis with polyangiitis, microscopic polyangiitis, relapse, remission, prednisolone, adverse events
- MeSH terms
- Adult, Aged, Azathioprine, Cyclophosphamide, Drug Therapy, Combination, Female, Glucocorticoids, Humans, Immunosuppressive Agents, Male, Middle Aged, Neutropenia, Prednisolone, Recurrence, Remission Induction, Vasculitis, Antibodies, Antineutrophil Cytoplasmic
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.